Stocktoria
INCYTE CORP INCY
Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 1993-12-06 · LEI
INCYTE CORP financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B | $2.7B | $2.2B | $1.9B | $1.5B | $1.1B |
| R&D expense | $2.1B | $2.6B | $1.6B | $1.6B | $1.5B | $2.2B | $1.2B | $1.2B | $1.3B | $581.9M |
| SG&A expense | $1.4B | $1.2B | $1.2B | $1.0B | $739.6M | $516.9M | $468.7M | $434.4M | $366.3M | $303.3M |
| Operating income | $1.5B | $61.4M | $620.5M | $579.4M | $585.8M | -$263.7M | $402.0M | $129.2M | -$243.4M | $145.0M |
| Interest expense | — | — | $2.6M | $2.7M | $1.9M | $2.2M | $1.9M | $1.5M | $6.9M | $38.7M |
| Income tax | $377.8M | $284.0M | $236.6M | $188.5M | -$378.1M | $63.5M | $39.9M | $5.9M | $852,000 | $3.2M |
| Net income | $1.3B | $32.6M | $597.6M | $340.7M | $948.6M | -$295.7M | $446.9M | $109.5M | -$313.1M | $104.2M |
| EPS (diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 |
| Operating cash flow | $1.4B | $335.3M | $496.5M | $969.9M | $749.5M | -$124.6M | $710.7M | $336.2M | -$93.0M | $304.8M |
| Cash & equivalents | $3.1B | $1.7B | $3.2B | $3.0B | $2.1B | $1.5B | $1.8B | $1.2B | $899.5M | $652.3M |
| Inventory | $101.1M | $58.9M | $63.0M | $42.0M | $27.9M | $16.4M | $11.4M | $7.0M | $6.5M | $4.1M |
| Total assets | $7.0B | $5.4B | $6.8B | $5.8B | $4.9B | $3.6B | $3.4B | $2.6B | $2.3B | $1.6B |
| Total liabilities | $1.8B | $2.0B | $1.6B | $1.5B | $1.2B | $949.6M | $828.3M | $719.8M | $672.0M | $1.2B |
| Shareholders' equity | $5.2B | $3.4B | $5.2B | $4.4B | $3.8B | $2.6B | $2.6B | $1.9B | $1.6B | $419.5M |
Growth · year-over-year · Revenue CAGR 18.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +21.2% | +14.8% | +8.9% | +13.7% | +12.0% | +23.5% | +14.7% | +22.5% | +38.9% | +46.7% |
| Net income growth | +3845.0% | -94.5% | +75.4% | -64.1% | — | -166.2% | +308.2% | — | -400.5% | — |
| EPS growth | +4173.3% | -94.3% | +74.3% | -64.4% | — | -166.3% | +302.0% | — | -383.3% | +1700.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.